Tumor Checkpoint and Immune System Profiling

 

 

As cancer evolves during disease progression, tumors often develop mechanisms to evade the body’s immune response.  A multitude of drugs targeting PD-1 and PD-L1—critical in T-cell recognition of a cell as foreign or self—are currently in development and have shown significant efficacy in subsets of patient cohorts with lung cancer and melanoma.  The identification of markers that are capable of predicting responses to these drugs has only just begun. 

Strategies for prediction employ:

  • Tumor tissue protein expression for PD-L1
  • Immune activation through the formation of TILs
  • Genomic analysis of tumors for the presence of MSI or mutational burden

All current strategies also have limitations due to the requirement of tissue. Evidence strongly suggests that sensitivity to immune checkpoint inhibitors and PD-L1 protein expression can increase with lines of systemic therapy. This supports the need for a real-time biopsy.

To identify patients who will most likely respond to immune checkpoint inhibitors, Epic Sciences has developed a number of tools, including a single cell PD-L1 IF assay.  This test has pinpointed PD-L1+ patients in a variety of diseases, including lung, bladder, pancreatic, breast and prostate cancer.  PD-L1+ CTCs have also identified worse outcomes in patients treated for lung cancer. 

Simultaneous tumor cell and leukocyte characterization

 
 
 

PD-l1+ ctcs prognosticate poor os in nsclc

 

Schedule in Seconds:

Code Click the image to refresh

Up to Date with Epic Sciences

Learn more about Epic Sciences' single cell PD-L1 assay and its applications in Lung and Bladder indications. Read our latest consortium presentations.